Semaglutide, a synthetic analog of glucagon-like peptide-1 (GLP-1), has garnered attention for its intriguing properties and potential implications in various r ...

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. These drugs have transformed the treatment of type 2 diabetes by helping lower blood sugar levels and even reducing the risk of ...

A study from the University of Gothenburg identifies specific brain neurons controlling semaglutide's weight loss effects.

Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Experts say that semaglutide and tirzepatide can help patients with heart failure lose weight, but limited NHS access is ...